Patricia Sarlos1,2, Kata Szemes1, Peter Hegyi1,2,3, Andras Garami2, Imre Szabo1, Anita Illes1, Margit Solymar2, Erika Petervari2, Aron Vincze1, Gabriella Par1, Judit Bajor1, Jozsef Czimmer1, Orsolya Huszar4, Peter Varju2,5, Nelli Farkas2,5,6. 1. Division of Gastroenterology, First Department of Medicine, University of Pécs, Pécs, Hungary. 2. Institute for Translational Medicine, University of Pécs, Pécs, Hungary. 3. Hungarian Academy of Sciences-University of Szeged, Momentum Gastroenterology Multidisciplinary Research Group, Szeged, Hungary. 4. First Department of Surgery, Semmelweis University, Budapest, Hungary. 5. Szentágothai Research Centre, University of Pécs, Pécs, Hungary. 6. Institute of Bioanalysis, University of Pécs, Pécs, Hungary.
Abstract
BACKGROUND AND AIMS: Inflammatory bowel disease [IBD] is associated with a 1.5- to 3-fold increased risk of venous thromboembolism [VTE] events. The aim of this study was to determine the risk of VTE in IBD as a complication of systemic corticosteroids and anti-tumour necrosis factor alpha [TNFα] therapies. METHODS: A systematic review and meta-analysis was conducted, which conforms to the Preferred Reporting Items for Systematic Reviews and Meta-analyses [PRISMA] statement. PubMed, EMBASE, Cochrane Library and Web of Science were searched for English-language studies published from inception inclusive of 15 April 2017. The population-intervention-comparison-outcome [PICO] format and statistically the random-effects and fixed-effect models were used to compare VTE risk during steroid and anti-TNFα treatment. Quality of the included studies was assessed using the Newcastle-Ottawa scale. The PROSPERO registration number is 42017070084. RESULTS: We identified 817 records, of which eight observational studies, involving 58518 IBD patients, were eligible for quantitative synthesis. In total, 3260 thromboembolic events occurred. Systemic corticosteroids were associated with a significantly higher rate of VTE complication in IBD patients as compared to IBD patients without steroid medication (odds ratio [OR]: 2.202; 95% confidence interval [CI]: 1.698-2.856, p < 0.001). In contrast, treatment with anti-TNFα agents resulted in a 5-fold decreased risk of VTE compared to steroid medication [OR: 0.267; 95% CI: 0.106-0.674, p = 0.005]. CONCLUSION: VTE risk should be carefully assessed and considered when deciding between anti-TNFα and steroids in the management of severe flare-ups. Thromboprophylaxis guidelines should be followed, no matter the therapy choice.
BACKGROUND AND AIMS: Inflammatory bowel disease [IBD] is associated with a 1.5- to 3-fold increased risk of venous thromboembolism [VTE] events. The aim of this study was to determine the risk of VTE in IBD as a complication of systemic corticosteroids and anti-tumour necrosis factor alpha [TNFα] therapies. METHODS: A systematic review and meta-analysis was conducted, which conforms to the Preferred Reporting Items for Systematic Reviews and Meta-analyses [PRISMA] statement. PubMed, EMBASE, Cochrane Library and Web of Science were searched for English-language studies published from inception inclusive of 15 April 2017. The population-intervention-comparison-outcome [PICO] format and statistically the random-effects and fixed-effect models were used to compare VTE risk during steroid and anti-TNFα treatment. Quality of the included studies was assessed using the Newcastle-Ottawa scale. The PROSPERO registration number is 42017070084. RESULTS: We identified 817 records, of which eight observational studies, involving 58518 IBD patients, were eligible for quantitative synthesis. In total, 3260 thromboembolic events occurred. Systemic corticosteroids were associated with a significantly higher rate of VTE complication in IBD patients as compared to IBD patients without steroid medication (odds ratio [OR]: 2.202; 95% confidence interval [CI]: 1.698-2.856, p < 0.001). In contrast, treatment with anti-TNFα agents resulted in a 5-fold decreased risk of VTE compared to steroid medication [OR: 0.267; 95% CI: 0.106-0.674, p = 0.005]. CONCLUSION: VTE risk should be carefully assessed and considered when deciding between anti-TNFα and steroids in the management of severe flare-ups. Thromboprophylaxis guidelines should be followed, no matter the therapy choice.
Authors: Pablo A Olivera; Stephane Zuily; Paulo G Kotze; Veronique Regnault; Sameer Al Awadhi; Peter Bossuyt; Richard B Gearry; Subrata Ghosh; Taku Kobayashi; Patrick Lacolley; Edouard Louis; Fernando Magro; Siew C Ng; Alfredo Papa; Tim Raine; Fabio V Teixeira; David T Rubin; Silvio Danese; Laurent Peyrin-Biroulet Journal: Nat Rev Gastroenterol Hepatol Date: 2021-08-27 Impact factor: 46.802
Authors: Brandon Amirian; Kyrillos M Akhnoukh; Asad M Ashraf; Samuel J Swiggett; Francis E Rosato; Rushabh M Vakharia; Ramin Sadeghpour; Afshin E Razi Journal: Shoulder Elbow Date: 2021-02-25
Authors: Su Young Kim; Yeon Seo Cho; Hyun-Soo Kim; Jung Kuk Lee; Hee Man Kim; Hong Jun Park; Hyunil Kim; Jihoon Kim; Dae Ryong Kang Journal: Gut Liver Date: 2021-11-18 Impact factor: 4.321
Authors: Péter Hegyi; Judit Bajor; Zsolt Szakács; Beáta Csiszár; Péter Kenyeres; Patrícia Sarlós; Bálint Erőss; Alizadeh Hussain; Ágnes Nagy; Balázs Kőszegi; Ibolya Veczák; Nelli Farkas; Emőke Bódis; Katalin Márta; Andrea Szentesi; Margit Tőkés-Füzesi; Tímea Berki; Áron Vincze; Kálmán Tóth Journal: BMJ Open Date: 2019-03-23 Impact factor: 2.692